Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05515575 · ClinicalTrials.gov registry record · Phase 2
A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA
A Phase 2 study of Sarcoma,Soft Tissue and Sarcoma Uterus, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 7
- Study locations
NCT05515575: Active Phase 2 study of Sarcoma,Soft Tissue and Sarcoma Uterus, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05515575 is a Phase 2 study of Sarcoma,Soft Tissue and Sarcoma Uterus that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 8 participants, below the 77-participant average among 12 other Sarcoma,Soft Tissue trials with a reported enrollment target (90% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05515575, a Phase 2 study of Sarcoma,Soft Tissue and Sarcoma Uterus, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to test whether the study drug, niraparib, is effective against unresectable and/or metastatic soft tissue sarcoma with DDR mutations. The researchers will also study whether niraparib is safe and causes few or mild side effects, and whether there are groups of DDR mutations in soft tissue sarcoma cells that respond better to treatment with niraparib.
Primary Outcome
Defined by RECIST 1.1. PFS is defined as the period from start of study treatment until recurrent or progressive of disease (POD) is objectively documented (taking as reference for progressive disease the smallest measurement recorded on study), death, or date of last study visit involving assessment of disease status.
Conditions Studied
Interventions
- DRUG Niraparib
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center Suffolk- Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Cancer Center (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-08-23 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
What the registry record for NCT05515575 still lists
NCT05515575 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 77-participant average among 12 other Sarcoma,Soft Tissue trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Sarcoma,Soft Tissue appearing as the primary indexed condition, and to 1 intervention - of which Niraparib is the first listed.
NCT05515575 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT05515575 about?
NCT05515575 is a clinical study titled "A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA". The purpose of this study is to test whether the study drug, niraparib, is effective against unresectable and/or metastatic soft tissue sarcoma with DDR mutations. The researchers will also study whether niraparib is safe and causes few or mild side effects, and whether there are groups of DDR mutat...
What is the current status of trial NCT05515575?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2022-08-23. Estimated completion is 2026-08.
What conditions does trial NCT05515575 study?
This clinical trial studies the following conditions: Sarcoma,Soft Tissue, Sarcoma Uterus.
What interventions are being tested in trial NCT05515575?
The interventions under investigation include: Niraparib (DRUG).
Who is sponsoring clinical trial NCT05515575?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05515575 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma,Soft Tissue
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05515575's enrollment target sits among peer trials
8 11th of 12 higher than 2 of 12 other Sarcoma,Soft Tissue trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma,Soft Tissue trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma
RECRUITING · Phase 2
-
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec
ACTIVE NOT RECRUITING · Phase 2
-
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
COMPLETED · Phase 2
-
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI